AURORA CANNABIS INC (ACB)
CA05156X8504 - Common Stock
ACB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. ACB has a bad profitability rating. Also its financial health evaluation is rather negative. ACB is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
ACB had negative earnings in the past year.
ACB had a negative operating cash flow in the past year.
In the past 5 years ACB reported 4 times negative net income.
In the past 5 years ACB always reported negative operating cash flow.
1.2 Ratios
ACB has a better Return On Assets (-16.39%) than 66.67% of its industry peers.
ACB has a Return On Equity of -25.93%. This is in the better half of the industry: ACB outperforms 70.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.39% | ||
| ROE | -25.93% | ||
| ROIC | N/A |
ROA(3y)-101.01%
ROA(5y)-60.91%
ROE(3y)-148.74%
ROE(5y)-89.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 1.93%, ACB is in line with its industry, outperforming 47.18% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ACB has more shares outstanding
Compared to 5 years ago, ACB has less shares outstanding
The debt/assets ratio for ACB is higher compared to a year ago.
2.2 Solvency
ACB has an Altman-Z score of -10.16. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
ACB's Altman-Z score of -10.16 is on the low side compared to the rest of the industry. ACB is outperformed by 75.90% of its industry peers.
ACB has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
ACB's Debt to Equity ratio of 0.15 is in line compared to the rest of the industry. ACB outperforms 46.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.16 |
ROIC/WACCN/A
WACC8.78%
2.3 Liquidity
ACB has a Current Ratio of 3.79. This indicates that ACB is financially healthy and has no problem in meeting its short term obligations.
ACB's Current ratio of 3.79 is in line compared to the rest of the industry. ACB outperforms 54.87% of its industry peers.
A Quick Ratio of 2.45 indicates that ACB has no problem at all paying its short term obligations.
ACB has a Quick ratio (2.45) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.79 | ||
| Quick Ratio | 2.45 |
3. Growth
3.1 Past
ACB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.02%, which is quite impressive.
Looking at the last year, ACB shows a very strong growth in Revenue. The Revenue has grown by 26.17%.
Measured over the past years, ACB shows a very strong growth in Revenue. The Revenue has been growing by 65.00% on average per year.
EPS 1Y (TTM)80.02%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-108.33%
Revenue 1Y (TTM)26.17%
Revenue growth 3Y-3.39%
Revenue growth 5Y65%
Revenue growth Q2Q4.44%
3.2 Future
Based on estimates for the next years, ACB will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.14% on average per year.
Based on estimates for the next years, ACB will show a very strong growth in Revenue. The Revenue will grow by 21.02% on average per year.
EPS Next Y-101.18%
EPS Next 2Y14.46%
EPS Next 3Y29.38%
EPS Next 5Y17.14%
Revenue Next Year55.98%
Revenue Next 2Y35.29%
Revenue Next 3Y27.89%
Revenue Next 5Y21.02%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ACB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ACB's earnings are expected to grow with 29.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.46%
EPS Next 3Y29.38%
5. Dividend
5.1 Amount
No dividends for ACB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AURORA CANNABIS INC
NASDAQ:ACB (4/22/2024, 7:00:00 PM)
After market: 6.2504 -0.03 (-0.47%)6.28
-0.18 (-2.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap98.76M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.39% | ||
| ROE | -25.93% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 1.93% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.15 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.79 | ||
| Quick Ratio | 2.45 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)80.02%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-101.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)26.17%
Revenue growth 3Y-3.39%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y